It’s the season of reinvention, resolution, and new beginnings. Is the biopharma industry ready for a revolutionary 2026? Here are some exciting trends ― and challenges ― to watch as we turn the page to the next exciting chapter in therapeutic innovation.
Digital stands to dominate drug manufacturing
Biopharma could benefit significantly from innovative technologies in 2026 as a dynamic digital landscape takes shape. This can be the year the industry moves faster and works smarter than ever before.
Continuing the shift toward automation will lead to more interconnected, intelligent manufacturing, reducing operational costs and helping to address the talent crunch with workflows requiring less manual intervention. And embracing AI modeling, machine learning, and predictive analytics has the potential to streamline process development and optimization, while also enhancing flexibility and supporting smooth scale up.
These new digital capabilities are also set to put quality and control front and center, with a surge in process analytical technology (PAT) expected in 2026. Cutting-edge tools, a regulatory push, and favorable return on investment have manufacturers leveraging real-time data, in-line sensors, remote monitoring, and cloud-based platforms to develop and produce therapeutics more reliably and efficiently.
What can threaten turning digital promise into progress in 2026?
New technology can be expensive up front ― and intimidating. Many companies don’t have the resources or confidence to integrate it. The biopharma industry can also be, understandably, particularly risk averse. Regulatory guidance around digital solutions is growing, but more direction is needed. And as innovative infrastructures send data into the cloud, failsafe ways of securing highly sensitive information will be essential to broad adoption.
Regulators gear up for more generics and biosimilars
There’s a steep decline coming in biopharma’s ongoing patent cliff, which will play an important role in transforming biopharma’s economic and regulatory landscape this year and into the near future. As widespread loss of exclusivity fuels generic and biosimilar competition, changes to agency policies and advances in technology will help regulators manage the anticipated influx of applications so these drugs can reach patients without delay.
But can the industry strike the sweet spot between efficiency and risk when determining biosimilarity?
The FDA has issued draft guidance to streamline biosimilar approvals, proposing a potential reduction in the number of required comparative studies and leaning more into analytics and functional characterization to demonstrate efficacy. This move signals an embrace of big data, marking a significant shift away from historical standards where long-running, serial clinical trials have served as the hallmark for drug approval. The fate of this policy ― and whether it builds sufficient confidence among patients, providers, and payers ― remains to be seen in 2026.
How can agencies maximize efficiency in this dynamic era of drug development?
To resourcefully manage time-consuming, complex processes amid an increase in regulatory activity, agencies are looking to disruptive technologies. Some of these innovative tools were implemented in 2025, with both the EMA and FDA launching AI-based programs to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets. As we move into 2026, these systems will be tested while the application of advanced analytics, AI-based models, natural language processing, and machine learning in the regulatory space continues to evolve.
Economic uncertainty a key driver of process intensification
With both encouraging and concerning signals heading into the new year, the fate of the global economy remains hard to predict for 2026. Even if a biopharmaceutical company is confident in its own financial standing, external pressures and an ambiguous environment are pushing leaders to proceed with caution.
As the industry looks for ways to cut costs and do more with less, process intensification will become a bigger area of focus in drug production. Rather than build a bigger facility, manufacturers are increasingly willing to revisit and re-engineer their processes to boost throughput using the resources they have. Small production footprints that are versatile, flexible, and agile will pave the way to success and safeguard against tough biopharma markets of today, and the future.
Another advantage of process intensification: sustainability. Optimizing and shrinking workflows opens the door to reducing waste and emissions, something the industry has attempted ― and struggled ― to prioritize in recent years amid economic pressures and financial demands. When business gains accompany reduced environmental impact, it’s a win-win.
How can biopharma leaders effectively intensify their processes in the new year?
To really leverage the long-term value of process intensification, leaders need to be willing to embrace change and some short-term pains. Much of which can boost productivity ― such as automation ― requires up-front investment. The industry’s change-averse conservative nature also comes into play, as the major process transformations that can come with intensification might be seen as risky.
Manufacturers can make the process more seamless and less risky by seeking comprehensive solutions and expertise, working with suppliers who can guide them through their intensification journey to simplify the lift from both a technological and regulatory perspective.
Innovative science steps closer to conquering cancer ― and more
2025 has primed the clinical pipeline with so much cutting-edge science, it’s hard to know where to look to find this year’s really big breakthrough. There could actually be many, with exciting advances happening in every direction across nearly all disease areas. And there’s no doubt oncology remains a hot spot.
Here are some modalities to watch in 2026:
- Antibody-drug conjugates (ADCs) have made their mark as a formidable candidate to transform cancer care in 2025. With a large number of clinical trials underway, ADCs could be making an even bigger splash this year.
- CAR T cell therapies will continue to play an important role in treatment strategies for blood cancers, with some progress expected in tackling solid tumors. In vivo CAR T is also quickly taking center stage, as using the body as a bioreactor can cut weeks of manufacturing time, simplify quality control, and drastically reduce cleanroom footprints to improve the accessibility and efficiency of cell therapy treatments.
- Other cell-based immunotherapies are set to further shape the clinical landscape, with engineered natural killer (NK) cells potentially offering more favorable safety profiles, more scalable manufacturing methods, and better accessibility over CAR T. These therapeutics are being investigated to treat cancer as well as autoimmune diseases.
- With advances in gene editing efficiency, RNA technologies, and viral vectors, gene-based modalities will continue to help address inheritable conditions, cancer, and communicable diseases. CRISPR is also showing promise in the regenerative medicine space, with edited stem cells being researched to treat diabetes, Alzheimer’s disease, and more.
Why does collaboration remain key to advancing therapeutics?
From the lab to GMP, across countries and continents, biopharma is big. Such a vast landscape calls on industry leaders to lean into collaboration, transparency, and silo breakdown to deliver on the industry’s promise. Drug development takes a village.
Advances in early-stage protein research methods and technologies ― often driven by academic labs ― are helping to identify better disease biomarkers and targets to direct the development of more effective, personalized regimens.
And an established drug can’t get to patients without reliable manufacturing. Solutions providers are constantly innovating to make processes faster and more consistent, require less raw materials, and operate more cost effectively at scale so drug developers can get their products to clinical trials and meet market demand.
With so much potential in the 2026 pipeline, this could be the year biopharma takes cross-industry synergy to the next level.
While there are plenty of signals to help us guess at the great things to come in biopharma this year, the most exciting part of the industry might be that it’s unpredictable… in the best way. One disruptive technology, a scientist’s accidental discovery, or a patient’s unexpected therapeutic response, and the entire landscape could be reshaped for the better in ways no one ever anticipated. We can’t wait to see what’s next.